The Global Health Body Issues Concern Over Critical Shortage of Weight-Loss Jabs
Fewer than one in 10 individuals eligible to benefit from GLP-1 drugs like Wegovy are able to get them, caution the global health agency as it publishes its initial guidance on the therapies.
Given over a billion people worldwide currently obese, it is calling for increased and just availability to these injectable treatments.
Based on forecasts, in excess of 2,000,000,000 are projected to be living with obesity by 2030 unless action is taken.
"Our latest guidelines acknowledges that excess weight is a long-term condition that can be addressed with holistic and lifelong treatment," stated its chief Tedros Adhanom Ghebreyesus.
High costs, constrained manufacturing, and supply-chain constraints are significant obstacles to universal access to the treatments that can aid individuals in losing considerable body mass, notes the body.
Skinny Jab Scarcity
Even under the present most optimistic scenario, the supply of such drugs could only cover around 100 million people – less than 10% of those who need them, as stated by the WHO.
The advice calls on countries and companies to increase availability, through measures including licensing agreements.
Exclusive production rights on a key compound – the core component of the drug Wegovy – is set to lapse in several countries in 2026.
How Obesity Jabs Operate
The injections replicate a body's own hormone to reduce digestion speed, reduce hunger and increase the sense of being full so people reduce food intake.
Patients usually see weight reduction within a few weeks of starting on the regular doses.
Studies points to patients may put most of the weight back on within a year of discontinuing the medication, because their normal food cravings resume.
Being carrying excess weight elevates your likelihood for contracting medical conditions, like type 2 diabetes, cardiovascular issues, stroke, and some malignancies.
Obesity affects people in all nations and was linked to millions of fatalities worldwide in 2024, according to the WHO.